Drugs / RV3-BB
RV3-BB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04344054 | Feb 2021 → Sep 2022 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase 2 | NCT03483116 | Jun 2018 → Jan 2020 | Rotavirus infection | Murdoch Childrens Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-08-31 | Medicines Development for Global Health | Results Safety and Immunogenicity of a Neonatal Rotavirus Vaccine in a Phase 2A study medicinesdevelopment.com ↗
The successful phase 2a study of RV3-BB provides proof-of-concept for vaccination in neonates using a human neonatal rotavirus strain, potentially providing a measure to extend vaccine coverage and uptake. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-08-31 | Medicines Development for Global Health | Safety and Immunogenicity of a Neonatal Rotavirus Vaccine in a Phase 2A study medicinesdevelopment.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RV3-BB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03483116 ↗ |
| Known as | RV3-BB Rotavirus Vaccine | “A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule...” NCT03483116 ↗ |
| Known as | RV3-BB vaccine | “RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk.” PMID 39339964 ↗ Sep 2024 |
| Modality | Vaccine | “RV3-BB vaccine” NCT03483116 ↗ |
| Route | Oral | “Oral administration” NCT03483116 ↗ |